在今年6月份的ASCO2017大会上,Bluebird/新基公布了靶向B细胞成熟抗原(BCMA)的CAR-T疗法bb2121在多发性骨髓瘤患者中的I期CRB-401研究的临床数据,当时共入组了18例接受过3~14种疗法、预期寿命只有大约8个月的高度晚期多发性骨髓瘤患者,其中15例接受了高剂量(≥150*106)bb2121的治疗,3个月时的客观缓解率达到100...
蓝鸟CAR-T疗法bb2121惊艳ASH2017 在今年6月份的ASCO2017大会上,Bluebird/新基公布了靶向B细胞成熟抗原(BCMA)的CAR-T疗法bb2121在多发性骨髓瘤患者中的I期CRB-401研究的临床数据,当时共入组了18例接受过3~14种疗法、预期寿命只有大约8个月的高度晚期多发性骨髓瘤患者,其中15例接受了高剂量(≥150*106)bb2121的...
提高CAR-T细胞对多发性骨髓瘤疗效的持久性,是包括新基在内的其余参与者的首要任务。在美国血液学会,新基和Bluebird展示了第二代anti-BCMA-CAR-T细胞疗法bb21217的早期数据,该数据显示出比迄今为止bb2121更好的耐久性。尽管如此,分析师仍然质疑新版CAR-T治疗方法是否比bb2121更加有效。 毫无疑问,随着对新基收购的进...
而审查顺利的话，bb2121将成为首款上市的BCMA-CAR-T疗法。然而变数不定，据昨日有关该产品审查的最新进展消息称，出于对其CMC模块的担忧，FDA拒绝了bb2121的上市申请，因此，尽管bb2121抢赢首款递交上市申请宝座，但鉴于紧跟其后的杨森/传奇的BCMA-CAR-T疗法--JNJ-4528虎视眈眈，bb2121真正成为首款上市靶向产品...
CAR-T的另一个新靶点BMCA早期数据显示比CD19安全性略好,针对BMCA的CAR-T药物BB2121在多发性骨髓瘤的安全性、应答率、应答持久性都不错。Cellectis的异体CAR-T药物UCART19在一期临床也显示不错疗效。但是实体瘤绝对是CAR-T必须攻克的适应症,否则上面提到的安全性、人群太小、竞争药物、高价格等因素将令现在这些CAR...
Celgene调整CAR-T骨髓瘤试验bb2121药物剂量 日前,新基(Celgene)表示,已经提高了其靶向人B细胞成熟抗原(BCMA)的CAR-T候选药物bb2121在试验中采用的最高治疗剂量,并扩大了试验规模。新基认为该药物将在2020年获得批准。 强生卡格列净降低心血管病风险新适应症申请遭美FDA推迟 ...
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple...
However, physicians are always looking to improve upon what has already been accomplished with CAR T-cell therapy. With current products, T-cell persistence lasts for approximately 6 to 9 months. The longer the T-cell persistence, the longer the potential remission, adds Raje. Early data ...
Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B cell maturation antigen (BCMA) has shown promising results for the treatment of relapsed refractory multiple myeloma (RRMM) in several phase 1 studies. Persistence of CAR T cells post infusion may be one determinant ...
Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial Kar... Ide-cel, a BCMA targeted CAR T cell therapy, showed promising tolerability and efficacy in RRMM pts in the phase I CRB-401 ...